Integrated Nanotherapeutics Revenue
Biotechnology Research • 
Burnaby, British Columbia, Canada • 11-20 Employees
Integrated Nanotherapeutics revenue & valuation
| Annual revenue | $1,283,325 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $4,200,000 |
| Total funding | No funding |
Key Contacts at Integrated Nanotherapeutics
Natalie Dakers
Member Board Of Directors
Josh Zaifman
Director, Chemistry
Sam Chen
Director, Formulation Development
Company overview
| Headquarters | 4475 Wayburne Drive, Suite 205, Burnaby, BC V5G 4X4, CA |
| Website | |
| SIC | 283 |
| Keywords | Nanotechnology, Diabetes, R&D, Immunology, Nanoparticles, Drug Delivery Systems, Autoimmune Diseases, Immune Tolerance, Formulation Process, Lipid Nanoparticles |
| Employees | 11-20 |
| Socials |
Integrated Nanotherapeutics Email Formats
Integrated Nanotherapeutics uses 4 email formats. The most common is {first name}{last name} (e.g., johndoe@integratedntx.com), used 63.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@integratedntx.com | 63.6% |
{first initial}{last name} | jdoe@integratedntx.com | 27.3% |
{last name}{last name} | doedoe@integratedntx.com | 9.1% |
About Integrated Nanotherapeutics
Integrated Nanotherapeutics Inc (INT) is a preclinical company developing antigen specific immune tolerance therapies using mRNA-Lipid nanoParticles (LNP). We have demonstrated that our mRNA-LNP therapy can reverse Type 1 Diabetes (T1D) in NOD mice. We were recently awarded a grant from Breakthrough T1D (formerly JDRF). With a growing pipeline in other T-cell-driven autoimmune diseases, we have successfully demonstrated in additional animal models that our tolerizing-LNP induces antigen-specific immune tolerance. Our proprietary technologies allow the incorporation of any compound in lipid nanoparticle delivery systems and thus extend the benefits of delivery systems to virtually any therapeutic and diagnostic agent. We envision that many existing drugs or agents can be made much safer and more effective using our technologies. We leverage this inherent capability of our platform technology to achieve antigen specific immune tolerance. We can deliver multiple antigens or epitopes due to the simplicity of using mRNA to express them. Additionally, we modify the immune response phenotype to these antigens by incorporating small-molecule immune modulators within the same LNP package.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Integrated Nanotherapeutics has 5 employees across 3 departments.
Departments
Number of employees
Funding Data
Integrated Nanotherapeutics has never raised funding before.
Integrated Nanotherapeutics Tech Stack
Discover the technologies and tools that power Integrated Nanotherapeutics's digital infrastructure, from frameworks to analytics platforms.
Font scripts
JavaScript libraries
JavaScript libraries
Development
Ecommerce
Security
Security
Miscellaneous
JavaScript libraries
Ecommerce
JavaScript libraries
CMS
United States
Central African Republic
Frequently asked questions
4.8
40,000 users
